Published in Structure on April 01, 2006
Role of the amphipathic peptide of Semliki forest virus replicase protein nsP1 in membrane association and virus replication. J Virol (2006) 1.20
The role of hydrophobic interactions in positioning of peripheral proteins in membranes. BMC Struct Biol (2007) 1.20
Structures of membrane proteins. Q Rev Biophys (2010) 1.11
Crystal structures of murine carnitine acetyltransferase in ternary complexes with its substrates. J Biol Chem (2006) 0.84
Crystal structure of rat carnitine palmitoyltransferase II (CPT-II). Biochem Biophys Res Commun (2006) 0.84
Abbreviated half-lives and impaired fuel utilization in carnitine palmitoyltransferase II variant fibroblasts. PLoS One (2015) 0.80
A monotopic membrane protein goes solo. Structure (2006) 0.79
Isothermal titration calorimetry with micelles: Thermodynamics of inhibitor binding to carnitine palmitoyltransferase 2 membrane protein. FEBS Open Bio (2013) 0.77
Stabilization of the thermolabile variant S113L of carnitine palmitoyltransferase II. Neurol Genet (2016) 0.76
Muscle Carnitine Palmitoyltransferase II Deficiency: A Review of Enzymatic Controversy and Clinical Features. Int J Mol Sci (2017) 0.75
Chromatin recruitment of activated AMPK drives fasting response genes co-controlled by GR and PPARα. Nucleic Acids Res (2016) 0.75
Assumed oxygen consumption frequently results in large errors in the determination of cardiac output. J Thorac Cardiovasc Surg (2005) 2.87
Unique carbohydrate-carbohydrate interactions are required for high affinity binding between FcgammaRIII and antibodies lacking core fucose. Proc Natl Acad Sci U S A (2011) 2.65
Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation (2002) 2.29
Insight into steroid scaffold formation from the structure of human oxidosqualene cyclase. Nature (2004) 1.86
Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. Radiology (2006) 1.68
Immunotherapy of peritoneal carcinomatosis with the antibody catumaxomab in colon, gastric, or pancreatic cancer: an open-label, multicenter, phase I/II trial. Onkologie (2011) 1.57
Systematic investigation of halogen bonding in protein-ligand interactions. Angew Chem Int Ed Engl (2011) 1.54
Effect of theophylline on contrast material-nephropathy in patients with chronic renal insufficiency: controlled, randomized, double-blinded study. Radiology (2002) 1.49
Assessment of long-term antihypertensive treatment by clinic and ambulatory blood pressure: data from the European Lacidipine Study on Atherosclerosis. J Hypertens (2007) 1.42
Structure of the acid-sensing ion channel 1 in complex with the gating modifier Psalmotoxin 1. Nat Commun (2012) 1.41
Gantenerumab: a novel human anti-Aβ antibody demonstrates sustained cerebral amyloid-β binding and elicits cell-mediated removal of human amyloid-β. J Alzheimers Dis (2012) 1.39
Modulating cholesteryl ester transfer protein activity maintains efficient pre-β-HDL formation and increases reverse cholesterol transport. J Lipid Res (2010) 1.38
The advantages of using a modified microbatch method for rapid screening of protein crystallization conditions. Acta Crystallogr D Biol Crystallogr (2003) 1.35
Quantification of cation-pi interactions in protein-ligand complexes: crystal-structure analysis of Factor Xa bound to a quaternary ammonium ion ligand. Angew Chem Int Ed Engl (2005) 1.20
Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. Structure (2003) 1.20
Structural properties of AMP-activated protein kinase: dimerization, molecular shape, and changes upon ligand binding. J Biol Chem (2008) 1.16
A novel partial agonist of peroxisome proliferator-activated receptor-gamma (PPARgamma) recruits PPARgamma-coactivator-1alpha, prevents triglyceride accumulation, and potentiates insulin signaling in vitro. Mol Endocrinol (2005) 1.11
Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haemato-oncological diseases: a prospective observational study. Br J Haematol (2003) 1.09
Two (betaalpha)(8)-barrel enzymes of histidine and tryptophan biosynthesis have similar reaction mechanisms and common strategies for protecting their labile substrates. Biochemistry (2002) 1.09
Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites. Int J Cancer (2011) 1.04
Novel slow- and fast-type drug release round-window microimplants for local drug application to the cochlea: an experimental study in guinea pigs. Audiol Neurootol (2004) 1.02
Structural and biophysical characterization of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers. Bioconjug Chem (2005) 1.00
Fluorine interactions at the thrombin active site: protein backbone fragments H-C(alpha)-C=O comprise a favorable C-F environment and interactions of C-F with electrophiles. Chembiochem (2004) 0.99
Crystal structures of Candida albicans N-myristoyltransferase with two distinct inhibitors. Chem Biol (2002) 0.98
Enhancing the stability and solubility of the glucocorticoid receptor ligand-binding domain by high-throughput library screening. J Mol Biol (2010) 0.98
pH probe positioning for 24-hour pH-metry by manometry or pH step-up. Eur J Gastroenterol Hepatol (2004) 0.97
Effect of a milk drink supplemented with whey peptides on blood pressure in patients with mild hypertension. Eur J Nutr (2006) 0.96
The structure of human α-2,6-sialyltransferase reveals the binding mode of complex glycans. Acta Crystallogr D Biol Crystallogr (2013) 0.96
Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations. J Mol Biol (2009) 0.95
β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease. J Med Chem (2013) 0.95
Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3). Cancer Res (2011) 0.94
Design of novel aminopyrrolidine factor Xa inhibitors from a screening hit. Eur J Med Chem (2009) 0.94
A fluorine scan of the phenylamidinium needle of tricyclic thrombin inhibitors: effects of fluorine substitution on pKa and binding affinity and evidence for intermolecular C-F...CN interactions. Org Biomol Chem (2004) 0.93
Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes. Bioorg Med Chem Lett (2009) 0.92
Crystal structures of uninhibited factor VIIa link its cofactor and substrate-assisted activation to specific interactions. J Mol Biol (2002) 0.92
Cation-pi interactions at the active site of factor Xa: dramatic enhancement upon stepwise N-alkylation of ammonium ions. Angew Chem Int Ed Engl (2009) 0.92
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research. J Med Chem (2011) 0.91
Metal-ion-dependent biological properties of a chelator-derived somatostatin analogue for tumour targeting. Chemistry (2008) 0.91
Role of the N-terminal extension of the (betaalpha)8-barrel enzyme indole-3-glycerol phosphate synthase for its fold, stability, and catalytic activity. Biochemistry (2005) 0.91
A fluorine scan of thrombin inhibitors to map the fluorophilicity/fluorophobicity of an enzyme active site: evidence for C-F...C=O interactions. Angew Chem Int Ed Engl (2003) 0.90
Biomolecular interaction analysis in drug discovery using surface plasmon resonance technology. Curr Pharm Des (2006) 0.90
Quality control of B-mode ultrasonic measurement of carotid artery intima-media thickness: the European Lacidipine Study on Atherosclerosis. J Hypertens (2005) 0.90
Crystal engineering yields crystals of cyclophilin D diffracting to 1.7 A resolution. Acta Crystallogr D Biol Crystallogr (2005) 0.89
X-ray structure of glutathione S-transferase from Schistosoma japonicum in a new crystal form reveals flexibility of the substrate-binding site. Acta Crystallogr Sect F Struct Biol Cryst Commun (2005) 0.89
Structure of the human fatty acid synthase KS-MAT didomain as a framework for inhibitor design. J Mol Biol (2010) 0.89
1,3-disubstituted 4-aminopiperidines as useful tools in the optimization of the 2-aminobenzo[a]quinolizine dipeptidyl peptidase IV inhibitors. Bioorg Med Chem Lett (2007) 0.89
Tyramine fragment binding to BACE-1. Bioorg Med Chem Lett (2008) 0.88
VEGF-C expression in squamous cell carcinoma and adenocarcinoma of the esophagus. World J Surg (2007) 0.88
Fragment-based screening using surface plasmon resonance technology. J Biomol Screen (2009) 0.87
The monotopic membrane protein human oxidosqualene cyclase is active as monomer. Biochem Biophys Res Commun (2004) 0.87
Carnitine palmitoyltransferase 2: analysis of membrane association and complex structure with a substrate analog. FEBS Lett (2007) 0.87
Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors. ChemMedChem (2012) 0.87
Effectiveness of theophylline prophylaxis of renal impairment after coronary angiography in patients with chronic renal insufficiency. Am J Cardiol (2003) 0.87
Molecular recognition of ligands in dipeptidyl peptidase IV. Curr Top Med Chem (2007) 0.87
Thymidine phosphorylase, dihydropyrimidine dehydrogenase and thymidylate synthase mRNA expression in primary colorectal tumors-correlation to tumor histopathology and clinical follow-up. Int J Colorectal Dis (2005) 0.87
Structure-assisted discovery of an aminothiazole derivative as a lead molecule for inhibition of bacterial fatty-acid synthesis. Acta Crystallogr D Biol Crystallogr (2007) 0.86
Discovery of carmegliptin: a potent and long-acting dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Bioorg Med Chem Lett (2009) 0.86
Novel hexahydrospiro[piperidine-4,1'-pyrrolo[3,4-c]pyrroles]: highly selective small-molecule nociceptin/orphanin FQ receptor agonists. J Med Chem (2003) 0.85
A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem (2005) 0.85
Molecular recognition at the active site of factor Xa: cation-π interactions, stacking on planar peptide surfaces, and replacement of structural water. Chemistry (2011) 0.85
Structural, kinetic, and thermodynamic analysis of the binding of the 40 kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug Chem (2005) 0.84
Mapping the conformational space accessible to BACE2 using surface mutants and cocrystals with Fab fragments, Fynomers and Xaperones. Acta Crystallogr D Biol Crystallogr (2013) 0.84